Good Laboratory Practices (GLP) – Page 5

GLP study documentation gaps during sponsor oversight – alignment with OECD principles

Identifying signs of GLP study documentation gaps at an early stage can prevent significant escalations. Key symptoms that should raise red flags in both laboratory and sponsor environments include:Click to…

Deviation handling weak during sponsor oversight – CAPA for GLP system gaps

Effective Strategies for Managing Deviations in GLP During Sponsor Oversight In the pharmaceutical and life sciences industries, effective deviation management during sponsor oversight can be a critical aspect that ensures…

GLP study documentation gaps during regulatory inspection – inspection deficiency risk analysis

Recognizing early signs of documentation gaps is critical to maintaining compliance with GLP principles. Identify the following symptoms during routine operations or inspections:Click to read the full article.

Analyst training deficiency during internal audit – inspection deficiency risk analysis

Recognizing the early symptoms or signals of analyst training deficiencies is imperative for effective management. Precursors to more severe issues can manifest in various ways, including:Click to read the full…

Raw data traceability failure during regulatory inspection – inspection deficiency risk analysis

Identifying early symptoms of raw data traceability failure can prevent larger compliance issues down the line. Common signals include:Click to read the full article.

GLP study documentation gaps during internal audit – CAPA for GLP system gaps

Identifying the signs of GLP documentation gaps during internal audits is crucial for timely intervention. Common symptoms that indicate potential issues include:Click to read the full article.

Archival process non-compliant during routine studies – preventing repeat GLP findings

Addressing Non-Compliant Archival Processes During Routine GLP Studies In the highly regulated pharmaceutical environment, compliance with Good Laboratory Practices (GLP) is critical. Non-compliance can lead to significant ramifications, including rejection…

Deviation handling weak during routine studies – CAPA for GLP system gaps

Playbook for Strengthening Deviation Handling in Routine Studies Deviation handling is a critical aspect of pharmaceutical manufacturing and quality assurance. Weaknesses in this area can lead to compliance risks, impacting…

Archival process non-compliant during routine studies – alignment with OECD principles

Identifying symptoms of archival process non-compliance can help in early intervention and mitigation of risks. Common signals include:Click to read the full article.